"Give with a free hand, but give only your own."
 -- J.R.R. Tolkien The Children of Hurin
- Multiple Sclerosis (MS) -

General Information:


See also CCSVI

The Multiple Sclerosis and Diet Saga
The McDougall Newsletter, Vol. 8, No. 1, January 2009
“Our figures show that at least 95% of people with MS that follow a low-fat [saturated fat] diet show no progression of disease.”

Here are some news articles about MS from Science Daily I ran across.

Multiple Sclerosis Successfully Reversed In Mice: New Immune-Suppressing Treatment Forces The Disease Into Remission

ScienceDaily (Aug. 12, 2009) — A new experimental treatment for multiple sclerosis (MS) completely reverses the devastating autoimmune disorder in mice, and might work exactly the same way in humans, say researchers at the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal...

New Pill To Treat Multiple Sclerosis

ScienceDaily (Apr. 30, 2009) — A new drug for multiple sclerosis can dramatically reduce the chances of a relapse or a deterioration of the condition, according to a new study from researchers at Queen Mary, University of London...

Little Pill Means Big News in the Treatment of Multiple Sclerosis

ScienceDaily (Jan. 26, 2010) — A new drug for multiple sclerosis promises to change the lives of the 100,000 people in the UK who have the condition, say researchers at Queen Mary, University of London. A major trial of the oral drug Cladribine -- results of which are published in the New England Journal of Medicine on 20 January 2010 -- has shown that it significantly reduces relapse and deterioration of the disease, and goes a long way to eliminating the unpleasant side effects associated with existing therapies. Cladribine promises to be the first ever treatment in tablet form for MS, and only needs be taken for between 8 to 10 days a year, eliminating the need for regular injections and intravenous infusions otherwise endured by sufferers. The ease with which Cladribine tablets can be administered, combined with its relatively few side effects, make it a hugely exciting development in the world of MS...

Inexpensive Hypertension Drug Could Be Multiple Sclerosis Treatment, Study Suggests

ScienceDaily (Aug. 19, 2009) — Turning serendipity into science, researchers at the Stanford University School of Medicine have found a link, in mice and in human brain tissue, between high blood pressure and multiple sclerosis. Their findings suggest that a safe, inexpensive drug already in wide use for high blood pressure may have therapeutic value in multiple sclerosis, as well... Next, the investigators turned to an equally well-established animal model: a laboratory-bred strain of mouse that, after being immunized with a particular chemical, develops brain lesions very similar to those observed in multiple sclerosis. When, before immunization with the disease-triggering chemical, mice got lisinopril dosages equivalent to those prescribed for humans with high blood pressure, they didn't develop the paralysis characteristic of disease progression. Strikingly, if it was given after the mice developed full-blown symptoms, lisinopril reversed their paralysis...

Note: lisinopril is available NOW. Even though it is a blood pressure drug, if it is safe to try, a physician can prescribe it "off label".

Promising Therapy for Relapsing Multiple Sclerosis

ScienceDaily (Feb. 18, 2010) — An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology...

Note: Daclizumab had been available in Europe. It was used to prevent rejection of transplanted organs, such as a kidney. Due to low sales volumes, the manufacturer no longer sells it. Perhaps this will change if it is effective against MS.

Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS.
Salinthone S, Yadav V, Bourdette DN, Carr DW.


The naturally occurring antioxidant lipoic acid (LA) was first described as an essential cofactor for the conversion of pyruvate to Acetyl-CoA, a critical step in respiration. LA is now recognized as a compound that has many biological functions. Along with its reduced form dihydrolipoic acid (DHLA), LA reduces and recycles cellular antioxidants such as glutathione, and chelates zinc, copper and other transition metal ions in addition to heavy metals. LA can also act as a scavenger of reactive oxygen and nitrogen species. By acting as an insulin mimetic agent, LA stimulates glucose uptake in many different cell types and can also modulate insulin signaling. The p38 and ERK MAP kinase pathways, AKT and NFkappaB are all regulated by LA. In addition, LA activates the prostaglandin EP2 and EP4 receptors to stimulate the production of the small molecule cyclic adenosine 5' monophosphate (cAMP). These diverse actions suggest that LA may be therapeutically effective in treating oxidative stress associated diseases. This review discusses the known biochemical properties of LA, its antioxidant properties, its ability to modulate signal transduction pathways, and the recent progress made in the utilization of LA as a therapeutic alternative for multiple sclerosis, Alzheimer's disease and diabetic neuropathy.

PMID: 18537699 [PubMed - indexed for MEDLINE]

The discovery detailed in the next article may be related to CCSVI.

Multiple Sclerosis Blocked in Mouse Model: Barring Immune Cells from Brain Prevents Symptoms

ScienceDaily (Mar. 7, 2011) — Scientists have blocked harmful immune cells from entering the brain in mice with a condition similar to multiple sclerosis (MS)...

Known sources:

Natural sources:


[for MS..]
Preliminary results of the treatment of a mouse model of Multiple Sclerosis with Anatabine.

New Drug Could Treat Alzheimer's, Multiple Sclerosis and Brain Injury
ScienceDaily (July 24, 2012) — A new class of drug developed at Northwestern University Feinberg School of Medicine shows early promise of being a one-size-fits-all therapy for Alzheimer's disease, Parkinson's disease, multiple sclerosis and traumatic brain injury by reducing inflammation in the brain… By addressing brain inflammation, the new class of drugs -- represented by MW151 and MW189 -- offers an entirely different therapeutic approach to Alzheimer's than current ones being tested… MW151 and MW189 work by preventing the damaging overproduction of brain proteins called proinflammatory cytokines…
[No PubMed citation yet]

Reviled Substance Involved in Alzheimer's Can Reverse Paralysis in Mice With Multiple Sclerosis
ScienceDaily (Aug. 1, 2012)
...In mice whose immune systems had been "trained" to attack myelin, which typically results in paralysis, A-beta injections delivered before the onset of symptoms prevented or delayed the onset of paralysis. Even when the injections were given after the onset of symptoms, they significantly lessened the severity of, and in some cases reversed, the mice's paralysis...

Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of  -Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis.
J. L. Grant, E. E. B. Ghosn, R. C. Axtell, K. Herges, H. F. Kuipers, N. S. Woodling, K. Andreasson, L. A. Herzenberg, L. A. Herzenberg, L. Steinman.
Science Translational Medicine, 2012; 4 (145): 145ra105 DOI: 10.1126/scitranslmed.3004145
[NO PubMed citation yet]

Preliminary results of the treatment of a mouse model of Multiple Sclerosis with Anatabine.

Roskamp Institute Reports Beneficial Effects of Nutritional Supplementation with Anatabine in an Animal Model of Multiple Sclerosis
Posted on May 8, 2012 by evan



More info: The Grand Index
Home  Preface  Brain Failure  Notes Notes II References pg. 1  References pg. 2
Nutritional Alternatives  Patricia's Protocol  Tauopathy Discussion Forum
Correspondence  Newsletters  Poems  Memory Enhancement

Click to join tauopathies


Questions or comments, contact "perpetualcommotion.com" at gmail.com

Updated: July 2, 2012
Inception: July 2, 2012